Search | Clinical Trials Finder

Conditions: Cytomegalovirus Infections, HIV Infections
Interventions: Sevirumab; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Birmingham, Alabama • Galveston, Texas

Conditions: Neovascular Age-related Macular Degeneration (nAMD)
Interventions: SOK583A1 (40 mg/mL), Prefilled Syringe (PFS); Drug · Device
Lead sponsor: Sandoz; Industry
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 3
States / cities: Marietta, Georgia • Oak Forest, Illinois • Liverpool, New York

Conditions: HIV Infections, Cytopenias
Interventions: Sargramostim; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years to 50 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Los Angeles, California • Boston, Massachusetts

Conditions: Rhinitis, Allergic, Seasonal
Interventions: Fluticasone furoate 27.5 mcg/actuation nasal spray (Lek Pharmaceuticals), Fluticasone furoate (Veramyst®) 27.5 mcg/actuation nasal spray, Placebo; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 12 Years and older
Enrollment: 727 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 7
States / cities: Austin, Texas • Kerrville, Texas • New Braunfels, Texas + 2 more

Conditions: Rheumatoid Arthritis
Interventions: GP2015; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Enrollment: 376 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 26
States / cities: Peoria, Arizona • Phoenix, Arizona • El Cajon, California + 21 more

Conditions: Metastatic NSCLC
Interventions: GME751, Keytruda-EU; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Enrollment: 218 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Fountain Valley, California

Conditions: Diarrhea, HIV Infections
Interventions: Octreotide; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 23
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 18 more

Conditions: Postmenopausal Women With Osteoporosis
Interventions: GP2411, EU-Prolia (EU-authorized Prolia®); Biological
Lead sponsor: Sandoz; Industry
Eligibility: 55 Years to 80 Years · Female only
Enrollment: 527 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 6
States / cities: Peoria, Arizona • Miami, Florida • Wichita, Kansas + 3 more

Conditions: Rheumatoid Arthritis
Interventions: Adalimumab - GP2017, Adalimumab - US licensed Humira; Biological
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Enrollment: 353 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2017
U.S. locations: 30
States / cities: Mesa, Arizona • Peoria, Arizona • Covina, California + 25 more

Conditions: HIV Infections, Cytopenias
Interventions: Zidovudine, Sargramostim; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Asthma
Interventions: fluticasone propionate/salmeterol (Flu/Sal) : 100mcg/50mcg, 250mcg/50mcg,500mcg/50 mcg; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 3
States / cities: Gainesville, Florida • Iowa City, Iowa • Madison, Wisconsin

Conditions: Birth Defects, Pregnancy Complications, Hepatitis C
Interventions: Not listed
Lead sponsor: Syneos Health; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 477 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2020
U.S. locations: 1
States / cities: Wilmington, North Carolina

Conditions: Neovascular Age-related Macular Degeneration
Interventions: SOK583A1 (40 mg/mL), Eylea EU (40 mg/mL); Biological
Lead sponsor: Sandoz; Industry
Eligibility: 50 Years and older
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 28
States / cities: Phoenix, Arizona • Arcadia, California • Campbell, California + 25 more

Conditions: HIV Infections, Cytopenias
Interventions: Interleukin-3; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Relapsing Multiple Sclerosis
Interventions: CYB704, Ocrevus-EU, Ocrevus-US; Biological
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 183 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Maitland, Florida • Ormond Beach, Florida

Conditions: Diarrhea, HIV Infections
Interventions: Octreotide; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 22
States / cities: Los Angeles, California • San Diego, California • San Francisco, California + 17 more

Conditions: Heart Transplantation, Kidney Transplantation, Liver Transplantation, Autoimmune Diseases
Interventions: Not listed
Lead sponsor: Genentech, Inc.; Industry
Eligibility: Female only
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2026
U.S. locations: 1
States / cities: Cambridge, Massachusetts

Conditions: Dry Skin
Interventions: AmLactin® Rapid Relief; Other
Lead sponsor: Sandoz; Industry
Eligibility: 50 Years and older · Female only
Enrollment: 56 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: High Point, North Carolina

Conditions: Rheumatoid Arthritis
Interventions: GP2013, MabThera, Rituxan; Biological
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Enrollment: 312 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 16
States / cities: Los Angeles, California • Lexington, Kentucky • Cumberland, Maryland + 13 more

Conditions: Melanoma
Interventions: GME751, Keytruda - EU, Keytruda - US; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Enrollment: 322 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 3
States / cities: Orange, California • Clermont, Florida • Orange City, Florida

Conditions: Neovascular Age-related Macular Degeneration (nAMD)
Interventions: SOK583A1; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 50 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022
U.S. locations: 5
States / cities: Poway, California • Marietta, Georgia • Oak Forest, Illinois + 2 more

Conditions: Renal Transplant
Interventions: Generic Tacrolimus, Branded Tacrolimus; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Cincinnati, Ohio • Philadelphia, Pennsylvania

Conditions: Rheumatoid Arthritis
Interventions: GP2013 - A Proposed biosimilar rituximab, Originator rituximab - Rituxan ® or MabThera ®; Biological
Lead sponsor: Sandoz; Industry
Eligibility: 18 Years and older
Enrollment: 107 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 39
States / cities: Huntsville, Alabama • Tuscaloosa, Alabama • Glendale, Arizona + 33 more

Conditions: Rhinitis, Allergic, Seasonal
Interventions: Mometasone furoate 50 mcg/actuation nasal spray (Lek Pharmaceuticals), Mometasone furoate (Nasonex®) 50 mcg/actuation nasal spray, Placebo; Drug
Lead sponsor: Sandoz; Industry
Eligibility: 12 Years and older
Enrollment: 795 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2010
U.S. locations: 8
States / cities: Austin, Texas • Kerrville, Texas • Live Oak, Texas + 3 more

Search by objective public record fields.

A Randomized, Phase I/II Trial to Assess the Safety and Antiviral Effects of Escalating Doses of A Human Anti-Cytomegalovirus Monoclonal Antibody (SDZ MSL-109) in Patients With the Acquired Immunodeficiency Syndrome and CMV Viremia and/or Viruria

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Prefilled Syringe

An Open Label Phase I Study of Subcutaneously Administered Recombinant Human GM-CSF in Patients With AIDS Virus Infection and Leukopenia

A Study Comparing Two Fluticasone Furoate Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis

Comparative Efficacy and Safety Study of GP2015 and Enbrel® in Patients With Rheumatoid Arthritis

A Study to Compare Efficacy, Safety, and Immunogenicity of GME751 and EU-authorized Keytruda in Adult Participants With Untreated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC)

A Multicenter Placebo-Controlled Dose Titration Study to Evaluate the Efficacy and Safety of Sandostatin (SMS 201-995) in the Treatment of Patients With Acquired Immunodeficiency Related Diarrhea

Study Investigating PK, PD, Efficacy, Safety, and Immunogenicity of Biosimilar Denosumab (GP2411) in Patients With Postmenopausal Osteoporosis

Clinical Trial to Compare Treatment With GP2017 and Humira® in Patients With Rheumatoid Arthritis

A Phase I/II Pilot Study of Simultaneously Administered Rhu GM-CSF ( CHO Cell ) and Azidothymidine ( AZT ) in Patients With Severe HIV Infection and Leukopenia: Pharmacokinetics and Feasibility

Pilot Study to Examine the Post-Dose Changes in Exhaled Nitric Oxide (eNO) Following Treatment With Fluticasone Propionate (FP)/Salmeterol (SAL) Combination Product Advair

The Ribavirin Pregnancy Registry

Phase III Study Assessing the Efficacy, Safety and Immunogenicity of SOK583A1 Versus Eylea® in Patients With Neovascular Age-related Macular Degeneration

A Phase I, Open Label Trial to Evaluate the Safety, Tolerance and Biological Effects of SDZ ILE-964 (Recombinant Human Interleukin-3, RhIL-3) in HIV Infected Patients With Cytopenia

Comparative PK, PD, Efficacy, and Safety Assessment of the Proposed Ocrelizumab Biosimilar CYB704 and Ocrevus in Participants With Relapsing Multiple Sclerosis

A Multicenter Placebo-Controlled Double Blind Study to Evaluate the Efficacy and Safety of Sandostatin ( SMS 201-995 ) in Patients With Acquired Immunodeficiency Related Diarrhea Who Were Either "Responders" or "Non-Responders" in a Prior Placebo-Controlled Double-Blind Sandostatin Study.

The Mycophenolate Pregnancy Registry

This Was a Clinical Study Investigating the Moisturization and Desquamation Effect of AmLactin® Rapid Relief Restoring Lotion + Ceramides on Dry Skin in Healthy Female Volunteers. AmLactin® Rapid Relief is an Over-the-counter Cosmetic

GP2013 in the Treatment of RA Patients Refractory to or Intolerant of Standard Therapy

A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma

Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit

Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients

GP2013 Treatment in Patients With Active Rheumatoid Arthritis, Previously Treated With Rituxan® or MabThera®

A Study Comparing the Clinical Equivalence of Two Mometasone Nasal Sprays in the Relief of the Signs and Symptoms of Seasonal Allergic Rhinitis